10x Genomics (TXG) to Release Earnings on Thursday

Key Points

• 10x Genomics is set to announce its Q2 2025 earnings results on August 7th, with analysts projecting an EPS of ($0.35) and revenue of $139.36 million for the quarter.
• In its last earnings report, 10x Genomics beat analysts' expectations, reporting an EPS of ($0.36) and revenue of $154.88 million, though its revenue decreased by 2.3% year-over-year.
• Insider trading activity included the sale of shares by CEO Serge Saxonov and other insiders in May, indicating some selling pressure on the stock.

10x Genomics (NASDAQ:TXG - Get Free Report) is projected to announce its Q2 2025 earnings results after the market closes on Thursday, August 7th. Analysts expect the company to announce earnings of ($0.35) per share and revenue of $139.36 million for the quarter. 10x Genomics has set its Q2 2025 guidance at EPS.

10x Genomics (NASDAQ:TXG - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The company reported ($0.36) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.45) by $0.09. 10x Genomics had a negative return on equity of 23.22% and a negative net margin of 25.14%. The company had revenue of $154.88 million during the quarter, compared to the consensus estimate of $131.91 million. During the same period in the previous year, the business earned ($0.50) EPS. 10x Genomics's revenue for the quarter was down 2.3% on a year-over-year basis. On average, analysts expect 10x Genomics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

10x Genomics Price Performance

Shares of NASDAQ TXG traded up $0.44 during midday trading on Monday, hitting $13.52. 1,401,052 shares of the company's stock were exchanged, compared to its average volume of 3,416,049. The firm's fifty day simple moving average is $11.51 and its 200-day simple moving average is $10.82. The company has a market cap of $1.66 billion, a PE ratio of -10.40 and a beta of 2.03. 10x Genomics has a twelve month low of $6.78 and a twelve month high of $24.76.

Insider Activity

In other 10x Genomics news, CFO Adam Taich sold 4,044 shares of the firm's stock in a transaction dated Thursday, May 22nd. The shares were sold at an average price of $8.30, for a total transaction of $33,565.20. Following the sale, the chief financial officer directly owned 331,588 shares of the company's stock, valued at $2,752,180.40. This trade represents a 1.20% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Serge Saxonov sold 9,343 shares of the business's stock in a transaction that occurred on Thursday, May 22nd. The shares were sold at an average price of $8.30, for a total transaction of $77,546.90. Following the completion of the transaction, the chief executive officer directly owned 1,083,625 shares of the company's stock, valued at approximately $8,994,087.50. This represents a 0.85% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 20,872 shares of company stock worth $173,238 over the last ninety days. 10.03% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of TXG. Goldman Sachs Group Inc. raised its position in shares of 10x Genomics by 163.5% in the 1st quarter. Goldman Sachs Group Inc. now owns 645,366 shares of the company's stock worth $5,634,000 after buying an additional 400,430 shares during the period. Royal Bank of Canada raised its holdings in shares of 10x Genomics by 806.4% in the 1st quarter. Royal Bank of Canada now owns 182,836 shares of the company's stock worth $1,597,000 after purchasing an additional 162,665 shares during the period. Finally, Focus Partners Wealth acquired a new position in shares of 10x Genomics in the 1st quarter valued at about $92,000. 84.68% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities research analysts have recently commented on TXG shares. Stephens restated an "overweight" rating and set a $14.00 price target on shares of 10x Genomics in a research note on Thursday, May 15th. The Goldman Sachs Group cut their price objective on shares of 10x Genomics from $7.50 to $6.50 and set a "sell" rating for the company in a research report on Monday, May 12th. Weiss Ratings reiterated a "sell (e+)" rating on shares of 10x Genomics in a research note on Tuesday, July 29th. Morgan Stanley lowered their price objective on 10x Genomics from $26.00 to $18.00 and set an "overweight" rating on the stock in a report on Monday, May 19th. Finally, Canaccord Genuity Group cut their target price on 10x Genomics from $18.00 to $15.00 and set a "buy" rating for the company in a research note on Monday, May 12th. One research analyst has rated the stock with a sell rating, six have given a hold rating and six have issued a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average target price of $13.23.

About 10x Genomics

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.